CTAD 2026

LEADER Study Session

 

Lecanemab More Than Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings

Copies of these presentations obtained through the QR code are for personal use only and may not be used without permission from CTAD and the authors of this presentation.